MoleMap, Australia and New Zealand’s leading skin cancer detection and surveillance service, has acquired Spotscreen, a regional and workplace skin check provider known for its mobile screening programs across Australia.

The acquisition strengthens MoleMap’s national footprint and accelerates its mission to improve early detection and access to specialist-led skin cancer care. 

MoleMap ANZ CEO Michelle Aquilina said the acquisition marks a significant step in expanding access to specialist-led skin cancer detection across Australia.

“Australia and New Zealand have the highest melanoma rates in the world, and MoleMap is building the most advanced skin cancer surveillance network to detect melanoma and skin cancer earlier, at scale,” Ms Aquilina said. 

“We are committed to pioneering early detection and improving outcomes across the ANZ region. 

“The acquisition of Spotscreen increases our ability to deliver our services to more of the population, both direct to consumer and through workplaces,” she continued. 

Spotscreen has built a strong reputation for delivering high-quality skin checks in regional and workplace environments. Integrating Spotscreen into the MoleMap network will extend specialist-led care to more Australians, particularly in communities where early detection can make a life-saving difference.

Spotscreen Corporate Director, Andrew Sheppard, said: “As a family-run business with a deep, personal connection to skin cancer, we have made it our mission to improve early detection rates and educate Australians on prevention.

“MoleMap’s clinical governance, technology and specialist network will allow Spotscreen to deliver even stronger outcomes for the people and organisations we serve,” said Mr Sheppard. 

Spotscreen clients – including corporate, mining, and government partners – will continue to receive the same services, with the added benefit of MoleMap’s advanced imaging, and skin surveillance pathways. 

Established in 2011, Spotscreen is dedicated to saving lives through early detection of skin cancers and delivering sun safety education in workplaces. 

Spotscreen will integrate into MoleMap’s clinical network, combining its mobile screening capability with MoleMap’s three-layer clinical model – trained melanographers, dermatologist assessment, and advanced imagery technology.